• Completed

NCT01723020: A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

NCT01723020: A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma


amg 232

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma


First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma


Sponsor:

Kartos Therapeutics, Inc.


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT01723020


Official Title: A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma

First Posted : November 7, 2012


Click here for details on ClinicalTrials.gov

 

Drug: AMG 232

 

AMG 232


Navtemadlin (Code C116624)

AMG 232

AMG-232

KRT 232

KRT-232

KRT232

MDM2 Inhibitor KRT-232

Navtemadlin

NAVTEMADLIN

 

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

Invest New Drugs;2020

Per local review, there were no responses. Stable disease (durability in months) was observed in patients with WDLPS (3.9), OST (3.3), DDLPS (2.0), GBM (1.8), and BC (1.4-2.0). Conclusions In patients with P53WT advanced solid tumors or MM, AMG 232 showed acceptable safety and dose-proportional pharmacokinetics, and stable disease was observed.


https://pubmed.ncbi.nlm.nih.gov/31359240/


 


Posts Archive